Evidence map›Paper›PMID 38701024›Full record

ArticleJournal of managed care & specialty pharmacy2024

The effectiveness and value of sotatercept for pulmonary arterial hypertension: A summary from the Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council.

Dmitriy Nikitin, Grace A Lin, Melanie D Whittington, Emily Nhan, Yasmine Kayali, David M Rind, Steven D Pearson, Foluso Agboola

Abstract read
In one paragraph

Article in Journal of managed care & specialty pharmacy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Journal of preventive medicine and hygiene · 2026
    Article
  2. Review
  3. Advancing the conversation: 30 years of scholarship in managed care pharmacy.Journal of managed care & specialty pharmacy · 2025
    Article
  4. Sotatercept: A First-In-Class Activin Signaling Inhibitor for Pulmonary Arterial Hypertension.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2025
    Review
  5. A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dmitriy NikitinInstitute for Clinical and Economic Review, Boston, MA.
Grace A LinInstitute for Clinical and Economic Review, Boston, MA.
Melanie D WhittingtonCenter for the Evaluation of Value and Risk in Health (CEVR), Tufts Medical Center, Boston, MA.
Emily NhanInstitute for Clinical and Economic Review, Boston, MA.
Yasmine KayaliInstitute for Clinical and Economic Review, Boston, MA.
David M RindInstitute for Clinical and Economic Review, Boston, MA.
Steven D PearsonInstitute for Clinical and Economic Review, Boston, MA.
Foluso AgboolaInstitute for Clinical and Economic Review, Boston, MA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Pulmonary Arterial HypertensionAdvisory CommitteesAntihypertensive AgentsComparative Effectiveness ResearchCost-Benefit AnalysisHumansTreatment OutcomeUnited StatesAntihypertensive Agents

Identifiers

PMID38701024
PMCPMC11068652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.